With a mechanism of action different from small molecule drugs and antibody drugs, small nucleic acid drugs are particularlysiRNA Has Unique Advantages and Great Potential:1) Wide target accessibility, 2) Strong targeting/specificity, 3) High R&D efficiency, 4) Long dosing interval.Based on the above characteristics, recentlyIn recent years, the global small nucleic acid drug field has seen significant developments.BD Deals occur intensively, such as2019NovartisA $9.7 billion blockbuster acquisition of The Medicine Company, and a $1 billion acquisition of DTx Pharma in 2023. Meanwhile,2023Starting from the year,siRNA Pipeline Licensing Shifts East to China, Represented by the Bo Wang and Novartis $4.1 Billion Pipeline DealThis YearIn September, a BD deal worth $5.36 billion ignited this track, indicatingChina's Small Nucleic AcidsDrugObtainedFavored by MNCs.Currently marketedThe representative drug of siRNA isLeqivo, co-developed by Alnylam and Novartis, 2021Pioneering in the United StatesApproved for marketing in China, used for treating adult primary hypercholesterolemia. Relying on the patient compliance advantage of a dosing interval lasting up to half a year,20Global sales in 24 years reached $750 million (+114%), approaching Praluent,2025 YearsThe First QuarterGlobal Sales$260 million (+72%), showing rapid growth.
Innovation Breakthrough, SiranBio CreationSmall Nucleic Acid Drugs2.0New Paradigm
Suzhou Siran Biotechnology Co.,Ltd.Founded in Suzhou in May 2022, it is a biotechnology company focused on the development of innovative siRNA drugs, established bysiRNA DrugsFounded jointly by a top team of scientists in the field of therapeutics and industrialization experts.The company has currently established industry-leading single-target and dual-target nucleic acid drug technology platforms with independent intellectual property rights, as well as an extrahepatic delivery platform, includingeSAFE chemical modification technology, STORK intrahepatic and extrahepatic delivery technology platform, and dual-target nucleic acid technology platform belong to the siRNA drug technology field.Version 2.0, occupying a leading position in the industry. Based on the above technical platform, the company has rapidly developed treatments for intrahepatic and extrahepatic...FIC and BIC small nucleic acid drug pipelines, including treatments for chronic hepatitis B, cardiovascular and metabolic diseases, autoimmune disorders, and central nervous system-related conditions.
The first product has been approved for clinical trials,Challenge AchievementFunctional Cure for Hepatitis B
In October 2025, SA1211 Injection, developed by SiranBio, received clinical trial approval from the CDE for the proposed treatment of chronic hepatitis B. SA1211 is the world’s first dual-target siRNA capable of simultaneously targeting the HBx gene of the hepatitis B virus and the PD-L1 gene in hepatocytes, and it is also the first single-molecule dual-target siRNA candidate drug to enter clinical trials internationally.Chronic Hepatitis B Virus (HBV) infection is one of the major disease challenges facing the world.，Current first-line clinical antiviral drugs include nucleoside (acid) analogs and interferons, which are difficult to achieve in chronic hepatitis B (Functional Cure of CHB, that is,Eliminate viral infection without rebound. SiranBio's dual-target strategy demonstrated promising efficacy in previous preclinical animal experiments, with no rebound after discontinuation of the treatment, offering hope for achieving functional cure in human clinical trials.
Zhongqi CapitalBelieve: In the past, globallyOver 20 years of exploration and practice have proven that siRNA drugs have shown excellent therapeutic effects on numerous rare diseases. After Alnylam, the leading company in the siRNA field, invented the GalNAc liver-targeting delivery technology, siRNA drugs began to make significant progress in the treatment of chronic diseases. Currently, many biotech companies worldwide (including numerous companies in China) are utilizing this delivery technology to develop siRNA drugs targeting PCSK9, APOC3, etc., achieving promising clinical progress, especially exemplified by the long-acting lipid-lowering drug Inclisiran. After overcoming the bottleneck of intrahepatic delivery, global research and development hotspots have gradually shifted toward the development of extrahepatic delivery and other new technological platforms, marking the era of siRNA 2.0. In this field, there is no generational gap in technology between companies in China and overseas; they are basically at the same starting line. Therefore, Chinese Biotech companies have the opportunity to overtake competitors and shine in the era of siRNA drugs. We believe that SiranBio, invested in by Zhongqi Capital, is a typical siRNA 2.0 company. Its dual-target liver-targeting technology and extrahepatic delivery technology are gaining recognition from peers both domestically and internationally, and the value of its technological platform will be gradually realized through clinical progress and future commercialization.
